{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T09:36:43Z","timestamp":1785317803481,"version":"3.55.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Remote electrical neuromodulation (REN) is a nonpharmacological acute migraine treatment that stimulates upper-arm peripheral nerves. The aim of this investigation was to evaluate the effectiveness and safety of REN for acute treatment of migraine in a real-world setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Real-world data were collected from patients who were using REN (Nerivio\u00ae, Theranica Bio-Electronics Ltd., Israel) between October 1, 2019, and March 31, 2020. Patients recorded their symptoms at baseline, two hours, and 24\u2009hours post-treatment. Patients were stratified based on the type of visit and provider; in-person visits with headache specialists (HS group) or virtual visits with nonheadache specialists (NHS group). Efficacy outcome focused on intra-individual consistency of response across multiple attacks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We found that 58.9% (662\/1,123) of the patients in the HS group and 74.2% (23\/31) of the patients in the NHS group experienced pain relief at two hours in at least 50% of their treated attacks and 20.0% (268\/1,339) of the patients in the HS group and 35.6% (16\/45) of the patients in the NHS group experienced pain freedom at two hours in at least 50% of their treated attacks. The effects of REN on associated symptoms and improvement in function were also consistent in both groups. The incidence of device-related adverse events was very low (0.5%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Real-world data confirm that REN results in meaningful clinical benefits with minimal side effects. REN may provide an effective drug-free treatment option for achieving consistent relief from migraine symptoms and may reduce the use of acute medications.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/pm\/pnaa299","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T19:44:26Z","timestamp":1596829466000},"page":"3522-3529","source":"Crossref","is-referenced-by-count":17,"title":["Real-world Experience with Remote Electrical Neuromodulation in the Acute Treatment of Migraine"],"prefix":"10.1093","volume":"21","author":[{"given":"Stewart J","family":"Tepper","sequence":"first","affiliation":[{"name":"The Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Lin","sequence":"additional","affiliation":[{"name":"Theranica Bio-Electronics Ltd., Netanya, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Montal","sequence":"additional","affiliation":[{"name":"Theranica Bio-Electronics Ltd., Netanya, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alon","family":"Ironi","sequence":"additional","affiliation":[{"name":"Theranica Bio-Electronics Ltd., Netanya, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Dougherty","sequence":"additional","affiliation":[{"name":"Department of Neurology, MedStar Georgetown University Hospital, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,16]]},"reference":[{"issue":"11","key":"2020122823520346900_pnaa299-B1","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","article-title":"Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"17","author":"Stovner","year":"2018","journal-title":"Lancet Neurol"},{"key":"2020122823520346900_pnaa299-B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"issue":"10","key":"2020122823520346900_pnaa299-B3","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2165\/11635440-000000000-00000","article-title":"Acute treatment of migraines","volume":"26","author":"Silva","year":"2012","journal-title":"CNS Drugs"},{"issue":"3","key":"2020122823520346900_pnaa299-B4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1474-4422(10)70005-3","article-title":"Current practice and future directions in the prevention and acute management of migraine","volume":"9","author":"Goadsby","year":"2010","journal-title":"Lancet Neurol"},{"issue":"8","key":"2020122823520346900_pnaa299-B5","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(04)00824-5","article-title":"Medication-overuse headache: A worldwide problem","volume":"3","author":"Diener","year":"2004","journal-title":"Lancet Neurol"},{"issue":"4","key":"2020122823520346900_pnaa299-B6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11916-009-0048-3","article-title":"Overuse of acute migraine medications and migraine chronification","volume":"13","author":"Bigal","year":"2009","journal-title":"Curr Pain Headache Rep"},{"issue":"7","key":"2020122823520346900_pnaa299-B7","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1212\/WNL.0000000000001256","article-title":"Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine","volume":"84","author":"Lipton","year":"2015","journal-title":"Neurology"},{"issue":"13","key":"2020122823520346900_pnaa299-B8","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1212\/WNL.0000000000003760","article-title":"Nonpainful remote electrical stimulation alleviates episodic migraine pain","volume":"88","author":"Yarnitsky","year":"2017","journal-title":"Neurology"},{"issue":"8","key":"2020122823520346900_pnaa299-B9","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/head.13551","article-title":"Remote electrical neuromodulation (REN) relieves acute migraine: A randomized, double-blind, placebo-controlled, multicenter trial","volume":"59","author":"Yarnitsky","year":"2019","journal-title":"Headache"},{"issue":"1","key":"2020122823520346900_pnaa299-B10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s10194-019-1033-9","article-title":"Remote electrical neuromodulation (REN) in the acute treatment of migraine: A comparison with usual care and acute migraine medications","volume":"20","author":"Rapoport","year":"2019","journal-title":"J\u00a0Headache Pain"},{"issue":"2","key":"2020122823520346900_pnaa299-B11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/SPC.0000000000000126","article-title":"Conditioned pain modulation","volume":"9","author":"Nir","year":"2015","journal-title":"Curr Opin Support Palliat Care"},{"issue":"2","key":"2020122823520346900_pnaa299-B12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1526-4610.1998.3802087.x","article-title":"Patterns of diagnosis, consultation, and treatment of migraine in the US: Results of the OVERCOME study","volume":"38","author":"Lipton","year":"1998","journal-title":"Headache"},{"issue":"3","key":"2020122823520346900_pnaa299-B13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/0333102410381145","article-title":"Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS)","volume":"31","author":"Blumenfeld","year":"2011","journal-title":"Cephalalgia"},{"issue":"10","key":"2020122823520346900_pnaa299-B14","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1111\/head.13421","article-title":"Health care resource utilization and migraine disability along the migraine continuum among patients treated for migraine","volume":"58","author":"Silberstein","year":"2018","journal-title":"Headache"},{"issue":"10","key":"2020122823520346900_pnaa299-B15","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1586\/ern.09.93","article-title":"Conceptualizing the relationship between chronic migraine and episodic migraine","volume":"9","author":"Lipton","year":"2009","journal-title":"Expert Rev Neurother"},{"issue":"10","key":"2020122823520346900_pnaa299-B16","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/head.13642","article-title":"Discontinuation of Acute prescription medication for migraine: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study","volume":"59","author":"Lipton","year":"2019","journal-title":"Headache"},{"issue":"2","key":"2020122823520346900_pnaa299-B17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1212\/WNL.0000000000004085","article-title":"A randomized trial of telemedicine efficacy and safety for nonacute headaches","volume":"89","author":"M\u00fcller","year":"2017","journal-title":"Neurology"},{"issue":"10","key":"2020122823520346900_pnaa299-B18","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1007\/s11606-018-4621-5","article-title":"Patterns of use and correlates of patient satisfaction with a large nationwide direct to consumer telemedicine service","volume":"33","author":"Martinez","year":"2018","journal-title":"J Gen Intern Med"},{"issue":"S1","key":"2020122823520346900_pnaa299-B19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1526-4610.2002.0420s1003.x","article-title":"What do patients with migraine want from acute migraine treatment?","volume":"42","author":"Lipton","year":"2002","journal-title":"Headache"},{"issue":"4","key":"2020122823520346900_pnaa299-B20","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/jnnp.2009.192492","article-title":"Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers","volume":"81","author":"Buse","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2020122823520346900_pnaa299-B21","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11916-011-0233-z","article-title":"Defining the differences between episodic migraine and chronic migraine","volume":"16","author":"Katsarava","year":"2012","journal-title":"Curr Pain Headache Rep"},{"issue":"7","key":"2020122823520346900_pnaa299-B22","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/j.1526-4610.2011.01945.x","article-title":"Cost of health care among patients with chronic and episodic migraine in Canada and the USA: Results From the International Burden of Migraine Study (IBMS)","volume":"51","author":"Stokes","year":"2011","journal-title":"Headache"},{"issue":"1","key":"2020122823520346900_pnaa299-B23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/head.12499","article-title":"The acute treatment of migraine in adults: The American Headache Society Evidence Assessment of Migraine Pharmacotherapies","volume":"55","author":"Marmura","year":"2015","journal-title":"Headache"},{"issue":"S2","key":"2020122823520346900_pnaa299-B24","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1111\/j.1526-4610.1999.00006.x","article-title":"Acute migraine therapy: Do doctors understand what patients with migraine want from therapy?","volume":"39","author":"Lipton","year":"1999","journal-title":"Headache"},{"issue":"8","key":"2020122823520346900_pnaa299-B25","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1111\/head.12150","article-title":"Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: Results of the American Migraine Prevalence and Prevention (AMPP) study","volume":"53","author":"Buse","year":"2013","journal-title":"Headache"},{"issue":"4","key":"2020122823520346900_pnaa299-B26","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/head.13766","article-title":"Ubrogepant, an acute treatment for migraine, improved patient-reported functional disability and satisfaction in 2 single-attack phase 3 randomized trials, ACHIEVE I and II","volume":"60","author":"Dodick","year":"2020","journal-title":"Headache"},{"key":"2020122823520346900_pnaa299-B27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-3-030-02976-0_2","volume-title":"Placebos and Nocebos in Headaches","author":"Negro","year":"2019"},{"issue":"4","key":"2020122823520346900_pnaa299-B28","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1212\/WNL.0000000000005857","article-title":"Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study","volume":"91","author":"Tassorelli","year":"2018","journal-title":"Neurology"},{"issue":"9294","key":"2020122823520346900_pnaa299-B29","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0140-6736(01)06711-3","article-title":"Oral triptans (serotonin 5-HT1B\/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials","volume":"358","author":"Ferrari","year":"2001","journal-title":"Lancet"},{"issue":"8","key":"2020122823520346900_pnaa299-B30","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1468-2982.2008.01806.x","article-title":"Consistency of response to sumatriptan\/naproxen sodium in a placebo-controlled, crossover study","volume":"29","author":"Lipton","year":"2009","journal-title":"Cephalalgia"},{"issue":"10","key":"2020122823520346900_pnaa299-B31","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1212\/WNL.55.10.1511","article-title":"Within-patient consistency of response of rizatriptan for treating migraine","volume":"55","author":"Dahlof","year":"2000","journal-title":"Neurology"},{"issue":"7","key":"2020122823520346900_pnaa299-B32","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/brain\/awz134","article-title":"Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine","volume":"142","author":"Goadsby","year":"2019","journal-title":"Brain"},{"issue":"10200","key":"2020122823520346900_pnaa299-B33","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","article-title":"Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: A randomised, phase 3, double-blind, placebo-controlled trial","volume":"394","author":"Croop","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"2020122823520346900_pnaa299-B34","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/head.13708","article-title":"Most bothersome symptom in persons with migraine: results from the Migraine in America Symptoms and Treatment (MAST) study","volume":"60","author":"Munjal","year":"2020","journal-title":"Headache"},{"issue":"2","key":"2020122823520346900_pnaa299-B35","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1811090","article-title":"Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine","volume":"381","author":"Lipton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"2020122823520346900_pnaa299-B36","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1177\/0333102416660552","article-title":"Comparative tolerability of treatments for acute migraine: A network meta-analysis","volume":"37","author":"Thorlund","year":"2017","journal-title":"Cephalalgia"},{"issue":"1","key":"2020122823520346900_pnaa299-B37","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1129-2377-14-95","article-title":"Safety and patients\u2019 satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly\u00ae device in headache treatment: A survey of 2,313 headache sufferers in the general population","volume":"14","author":"Magis","year":"2013","journal-title":"J Headache Pain"},{"issue":"19","key":"2020122823520346900_pnaa299-B38","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jama.2019.16711","article-title":"Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: The ACHIEVE II randomized clinical trial","volume":"322","author":"Lipton","year":"2019","journal-title":"JAMA"},{"issue":"11","key":"2020122823520346900_pnaa299-B39","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1185\/03007990903285449","article-title":"Postmarketing migraine survey of frovatriptan: Effectiveness and tolerability vs previous triptans, NSAIDs or a combination","volume":"25","author":"Cady","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"2020122823520346900_pnaa299-B40","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000085040","article-title":"Efficacy and tolerability of almotriptan in postmarketing surveillance studies","volume":"53","author":"Pascual","year":"2005","journal-title":"Eur Neurol"}],"container-title":["Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/painmedicine\/article-pdf\/21\/12\/3522\/35206323\/pnaa299.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/painmedicine\/article-pdf\/21\/12\/3522\/35206323\/pnaa299.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T05:09:20Z","timestamp":1609218560000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/painmedicine\/article\/21\/12\/3522\/5906300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":40,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,9,16]]},"published-print":{"date-parts":[[2020,12,25]]}},"URL":"https:\/\/doi.org\/10.1093\/pm\/pnaa299","relation":{},"ISSN":["1526-2375","1526-4637"],"issn-type":[{"value":"1526-2375","type":"print"},{"value":"1526-4637","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,9,16]]}}}